{"id":417214,"date":"2026-05-08T01:57:08","date_gmt":"2026-05-08T01:57:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/417214\/"},"modified":"2026-05-08T01:57:08","modified_gmt":"2026-05-08T01:57:08","slug":"guess-which-asx-healthcare-stock-could-rocket-70","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/417214\/","title":{"rendered":"Guess which ASX healthcare stock could rocket 70%"},"content":{"rendered":"

Neuren Pharmaceuticals Ltd (ASX: NEU<\/a>) shares are having a strong week.<\/p>\n

This has been driven by a positive reaction to the release of a quarterly sales update<\/a>.<\/p>\n

The good news is that Bell Potter believes this ASX healthcare stock could still have significant upside potential over the next 12 months.<\/p>\n

Let’s see what the broker is saying about the pharmaceuticals company.<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

What is the broker saying?<\/p>\n

Bell Potter was pleased with Neuren’s update, highlighting that Daybue sales were higher than it was forecasting during the first quarter. It said:<\/p>\n

NEU’s commercial partner, Acadia Pharmaceuticals, provided a 1Q26 Daybue sales update, from which NEU receives royalties and milestones. Daybue sales were US$101.2m (+20% on pcp and -8% qoq), a beat to BPe US$96m albeit modestly below Acadia’s US analyst VA cons of US$104m. The 20% growth rate is a welcome uplift from the 11-14% growth in each of the last 5 quarters.<\/p>\n

The broker points out that the new Daybue STIX offering is proving to be a strong addition to the portfolio. It adds:<\/p>\n

A key driver of the step-up has been the launch of the new powder formulation, called Daybue STIX. Importantly, the improved convenience and flexibility of STIX is helping bring treatment-na\u00efve and previously discontinued patients onto treatment rather than just converting existing patients. Roughly 30% of the 250 STIX patient prescriptions during 1Q were treatment-na\u00efve or previously discontinued patients (split 1:1).<\/p>\n

Another positive according to Bell Potter is that Daybue guidance for 2026 is looking achievable following this strong start to the year. The broker explains:<\/p>\n

Acadia reaffirmed bullish CY26 Daybue guidance of US$460-490m sales, implying 18-25% growth. The +20% growth in Q1 falls within this ambitious range, thus confidence in meeting guidance is increased. At the end of the day, NEU receive a 10-12% royalty on sales, thus a few million +\/- at the sales line makes relatively negligible impact to NEU; importantly, royalties show no sign of easing any time soon.<\/p>\n

Following the result, we increase Daybue Nth American sales forecasts, however this is offset by removing previously heavily risk-adjusted EU sales. A reversal of the EMA’s original decision in June is not expected but would be a welcome surprise.<\/p>\n

ASX healthcare stock tipped to rocket<\/p>\n

According to the note, the broker has retained its buy rating and $22.00 price target on Neuren’s shares.<\/p>\n

Based on its current share price of $13.05, this implies potential upside of almost 70% for investors over the next 12 months.<\/p>\n

Commenting on its recommendation, Bell Potter said:<\/p>\n

No changes to our $22.00 PT or BUY recommendation. NEU’s biggest priority is quickly activating the 20+ US clinical sites and enrolling the 160 patients for its Phase 3 trial of NNZ-2591 in Phelan McDermid syndrome. The readout from this Phase 3 trial is the next company-defining catalyst event for NEU albeit remains some time away (end-CY27 pending recruitment). Before then, we will be looking out for updates in NNZ-2591’s other indications throughout 2H CY26, such as Pitt Hopkins and HIE.<\/p>\n","protected":false},"excerpt":{"rendered":"Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a strong week. This has been driven by a positive…\n","protected":false},"author":2,"featured_media":417215,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[134,527,111,139,69],"class_list":["post-417214","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/417214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=417214"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/417214\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/417215"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=417214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=417214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=417214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}